 BridgeBio Pharma, Inc. BridgeBio Nasdaq:BBIO and Eidos Therapeutics, Inc. Eidos EIDX, today presented positive data from the companies ongoing Open Label Extension OLE of the Phase 2 clinical trial studying AG10 in patients with symptomatic transthyretin TTR amyloidosis cardiomyopathy ATTR-CM. ATTR-CM is a progressive and fatal disease that is an under recognized cause of heart failure. 